The efficacy of dapagliflozin combined with hypoglycemic drugs in treating type 2 diabetes: protocol for meta-analysis of randomized controlled trials

BACKGROUND: Dapagliflozin is a first-in-class oral sodium glucose co-transporter 2 (SGLT2) inhibitor. It is often used in combination with conventional anti-diabetic drugs such as metformin, glimepiride, and insulin in treating type 2 diabetes (T2D). It not only reduces glucose reabsorption in the k...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Sun, Yu-nan, Zhou, Yi, Chen, Xi, Che, Wen-si, Leung, Siu-wai
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Protocol
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3833641/
https://ncbi.nlm.nih.gov/pubmed/24225054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2046-4053-2-103
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky